You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. SapC-DOPS Nanovesicles for Treating Glioblastoma Multiforme

    SBC: BEXION PHARMACEUTICALS, INC.            Topic: 102

    DESCRIPTION provided by applicant Our goal is to develop a new molecular entity with a novel mechanism of action for targeting and eliminating glioblastoma multiforme GBM high grade glioma a deadly and invasive brain tumor with no effective treatment Of the patients expected to be diagnosed with GBM this year most will succumb within a year There is an urgent demand for an efficac ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Hollow Fiber Catheter for Drug Delivery into the Prostate

    SBC: TWIN STAR TDS, LLC            Topic: 300

    DESCRIPTION provided by applicant The significance of the proposed research is based on the growing demand for healthcare resources to treat and manage prostatic disease particularly benign prostatic hyperplasia BPH and cancer Both the incidence and cost of treatment for BPH and its complications are growing rapidly with the aging U S population prostate cancer is the second leading cau ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Selection-driven plant metabolites for treatment of CNS diseases

    SBC: NAPROGENIX, INC.            Topic: 150

    DESCRIPTION provided by applicant This project aims to demonstrate that the evolution of plant biosynthetic pathways can be accelerated and driven to favor the synthesis of ligands which interact with a specific human target protein This is achieved by subjecting mutant plant cells to selection pressures favoring the survival of mutants with the phenotype of interest As an example this appro ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Intelligent and Automatic Image Segmentation Software for High ThroughputAnalysi

    SBC: CytoInformatics LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): It is well established that aging and many chronic diseases, such as cancer and heart failure, are associated with significant losses in skeletal muscle mass and strength in humans. There is agreement across the musclebiology community that important morphological characteristics of muscle fibers, such as fiber area, the number and position of myonuclei, cellul ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. human Microvessel Culture System (hMCS)

    SBC: ANGIOMICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Human Microvessel Culture System (hMCS) Angiogenesis-targeting therapies, either inhibiting or promoting new vessel growth, have the potential for treating numerous diseases including cancer, eye diseases, cardiac and peripheral vascular disease, skin disorders, fibro-proliferative diseases, and inflammatory conditions such as arthritis. Furthermore, growing ev ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Naloxone Nasal Spray Development

    SBC: ANTIOP, INC.            Topic: NIDA

    DESCRIPTION: The following proposal is a follow-on Phase 2 b application from our initial proposal (1-R42 DA 030001). U.S. drug overdose deaths, mostly commonly from opioids, now exceed deaths from automobile accidents. There is a significant unmet medical need to provide additional pharmacologic options for treatment of opioid overdose. Emergency medical service personnel would prefer a non- inj ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Advanced training platform and methodologies for emergency responders and skilled

    SBC: PARATECHS CORP.            Topic: NIAID

    DESCRIPTION (provided by applicant): The baculovirus expression vector system (BEVS) has been successfully utilized to produce thousands of proteins for use as vaccines, therapeutics, and for structure-function studies. One limitation of BEVS is the propensity of baculoviruses to accumulate transposon insertions into the fp25k gene leading to the few polyhedra (FP) phenotype. This mutation shift ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. New drug VS-110 for treating inflammatory bowel diseases

    SBC: KENTUCKY IMAGING TECHNOLOGIES, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Colorectal cancer is the third most common form of cancer and the second leading cause of cancer-related death in the US. Yet, if polyps are detected and removed early, colorectal cancer is largely preventable. Althoughoptical colonoscopy (OC), the current gold standard, detects more than 90% of colorectal neoplasms; it is invasive and can be uncomfortable, inc ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Electro-Optically Modulated SPR: Densely Multiplexed High-Sensitivity Biosensor

    SBC: Bluegrass Advanced Materials, LLC            Topic: NIDCR

    DESCRIPTION (provided by applicant): Every year in the United States, approximately 132,000 patients undergoing anti-cancer therapy develop oral mucositis (OM), a painful, debilitating oral wound condition, which is estimated to increase the patient's cost of care by 17,000-43,000. Most treatments have focused on either palliative care or accelerating the wound healing process through the a ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government